New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:25 EDTABBV, ABBV, AET, AET, AMGN, AMGN, ESRX, ESRX, HSP, HSP, MNTA, MNTA, PFE, PFEFTC to hold a workshop
The Biologics Workshop explores competition issues involving biologic medicines and follow-on biologics with a focus on the potential impact of state regulations affecting competition. Companies participating include AbbVie, Aetna, Amgen, Express Scripts, Hospira, Momenta Pharmaceuticals and Pfizer at the FTC Washington, D.C. offices on February 4 at 8:30 am. Webcast Link
News For ABBV;AET;AMGN;ESRX;HSP;MNTA;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 13, 2015
08:34 EDTABBVAbbVie upgraded on Imbruvica outlook at BMO Capital
Subscribe for More Information
07:33 EDTAETJefferies sees low probability of WellCare, Centene buyouts
After running several acquisition scenarios for the Managed Care space, Jefferies says potential takeovers of WellCare (WCG) and Centene (CNC) are "hard to justify." The firm estimates acquirers will only be able to generate 1%-3% accretion from buying either company at a 20% premium to current share prices. The deal that makes the most financial sense is Aetna (AET) buying Cigna (CI), Jefferies says today in a note to investors. Also financially attractive would be a buyout of Humana (HUM) by either Anthem (ANTM) or Aetna, the firm adds. After analyzing the Managed Care space, it upgraded this morning shares of UnitedHealth (UNH) to Buy from Hold with a $141 price target. Jefferies also has Buy ratings on Aetna, Anthem, Health Net (HNT) and Molina Healthcare (MOH).
07:02 EDTABBVAbbVie upgraded to Outperform from Market Perform at BMO Capital
April 9, 2015
14:15 EDTESRXExpress Scripts calls active on elevated volatility on sharp rally
Express Scripts April weekly 87 and April 90 calls are active on total call volume of 20K (2K puts). April weekly call option implied volatility is at 38, April is at 26, May is at 30, June is at 25; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement.
09:51 EDTPFEPerrigo did not expect Mylan takeover letter, CNBC's Faber reports
Perrigo (PRGO) did not expect the takeover letter it received from Mylan (MYL), CNBC's David Faber reports, citing sources. Perrigo will take its time in deciding what its next steps are, Faber added. Shares of Mylan are up 3% in early trading, which is being attributed, at least in part, to speculation the company could be a takeover target itself. Analysts this morning mentioned Teva (TEVA) as a potential acquirer of Mylan. Chatter this morning has Pfizer (PFE) also potentially interested in the EpiPen maker
09:25 EDTPFEPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
08:04 EDTPFEPfizer launches PCSK9 competitive grants program
Subscribe for More Information
April 8, 2015
11:52 EDTMNTAMomenta downgraded to Neutral from Buy at UBS
Subscribe for More Information
05:30 EDTABBVEnanta announces data on regimens containing protease inhibitors paritaprevir
Subscribe for More Information
April 7, 2015
11:02 EDTHSPHospira responds to FDA warning letter
Subscribe for More Information
10:23 EDTAETMedicare Advantage 2016 rates set above expectations
The U.S. yesterday announced higher than expected 2016 Medicare Advantage reimbursement rates. The news is seen as benefiting managed care companies with large exposure to the Medicare Advantage program. WHAT'S NEW: The Centers for Medicare and Medicaid Services, or CMS, yesterday afternoon announced that Medicare Advantage reimbursement rates would rise 1.25% in 2016 from 2015 levels. In February, CMS proposed a 0.95% reduction in Medicare Advantage reimbursement rates for 2016. This year, reimbursement rates have fallen 4%. WHAT'S NOTABLE: Humana (HUM) said this morning in a regulatory filing that based on its review of the Final Rate Notice, the company expects an average Medicare Advantage funding increase for its business of approximately 0.8% from CMS for 2016, versus a funding decline of 1.25%-1.75% previously expected based on the Advance Notice. Humanaís estimated year-over-year funding increase as it affects the company is projected to be less than the CMS estimate for the MA program primarily due to Humanaís view of the projected impact associated with CMSí 2016 adjustment to the risk model calculation, the company explained. ANALYST REACTION: In a note to investors earlier today, Deutsche Bank analyst Scott Fidel wrote that this is the first time in seven years that CMS has implemented an increase in Medicare Advantage rates. However, noting that CMS said it had raised its estimates for Medicare costs, Fidel added that this forecast tempered the positive outlook created by the reimbursement increase. The analyst kept Buy ratings on the following stocks in the sector: Aetna (AET), Anthem (ANTM), Cigna (CI), Magellan Health (MGLN), and UnitedHealth (UNH). Stifel analysts said that the results were modestly better than expected, except for the agency's decision not to make a Star rating adjustment for plans with certain higher acuity populations. The firm thinks that more diversified managed care companies with Medicare Advantage products could be boosted by CMS' decision, identifying Aetna, Humana, and UnitedHealth as being among the companies in that category. PRICE ACTION: In early trading, Aetna was little changed at $107.40, Anthem was flat near $155 per share, Cigna slipped 0.4% to $131.34, Magellan was flat at $71, UnitedHealth added 0.5% to $118.31 and Humana gained fractionally to $178.54.
09:30 EDTHSPHospira sent FDA warning letter following site inspection
The FDA sent a warning letter to Hospira, dated March 31, following a May 5-9 and 12-13, 2014 inspection of the company's pharmaceutical manufacturing facility. "We have conducted a detailed review of your firmís response dated June 4, 2014 and note that it lacks sufficient corrective actions. We acknowledge receipt of your firmís correspondence dated August 4, 2014, October 2, 2014, December 4, 2014, and February 9, 2015," the FDA states in its letter. Reference Link
08:20 EDTAETCowen expects managed care stocks to outperform following CMS release
Cowen expects managed care stocks to outperform today following the CMS release outlining better than expected Medicare Advantage rates for 2016. The firm also sees improved FFS growth rates, maintained coding intensity adjustment, and continued HRA payments. Publicly traded companies in the space include Aetna (AET), Cigna (CI), Health Net (HNT), Humana (HUM), and WellCare (WCG).
08:09 EDTPFEPfizer, Merck KGaA finalize agreement to co-promote XALKORI
Merck KGaA (MKGAY) and Pfizer (PFE) announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizerís anaplastic lymphoma kinase inhibitor XALKORI. Under the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries: France, Germany, Italy, Spain and the United Kingdom. In the U.S. and Canada, XALKORI will be co-promoted by EMD Serono, the U.S. and Canadian biopharmaceutical businesses of Merck KGaA. The second wave will begin in 2016 and includes China and Turkey. n 2015, Merck KGaA will receive a reimbursement associated with its promotion of XALKORI, followed by an 80% for Pfizer, 20% for Merck KGaA profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the U.S., Canada, Japan, France, Germany, Italy, Spain and the U.K. and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck KGaA.
07:44 EDTAETSome managed care stocks could be boosted by CMS decision, says Stifel
Subscribe for More Information
07:41 EDTAET2016 MA rates positive for first time in seven years, says Deutsche Bank
Deutsche Bank notes that for the first time since 2009, Medicare Advantage rates will be positive after the Centers for Medicare and Medicaid Services announced yesterday that final 2016 rates will rise by 1.25%, representing a 220 basis points favorable swing from the preliminary proposed cut of 0.95%. Deutsche says the positive surprise is "somewhat tempered" by the more cautious view on Medicare cost trends provided by the CMS actuaries in the final 2016 rate announcement. The firm expects Humana (HUM), Health Net (HNT) and UnitedHealth (UNH), Aetna (AET) and Anthem (ANTM) to experience Medicare Advantage rate increases.
07:31 EDTABBVBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
07:14 EDTPFEEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
07:02 EDTPFEGlycoMimetics updates on Pfizer's plans to initiate Phase 3 Rivipansel trial
Subscribe for More Information
06:56 EDTAETAetna CEO sees 'groundswell' of wage increases in coming months, WSJ reports
Mark Bertolini, the CEO of Aetna, says he believes there will be a "groundswell" of pay increases for the lowest-paid employees at big companies in the next few months, The Wall Street Journal reports. Bertolini commented at a Peterson Institute for International Economics event that he believes "there are a number of CEOs that will come out in the next six months with wage increases that will matter." Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use